Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | DHPS | P49366 | 1/20 | 0.61 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.59 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.59 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5306840 | 1.00 | MEN1 (1.00) | MEN1KMT2ADHPSPRSS1PRSS2 | |
| SCHEMBL1249219 | 1.00 | MEN1 (1.00) | MEN1KMT2ADHPSPRSS1PRSS2 | |
| SCHEMBL5597193 | 1.00 | MEN1 (1.00) | MEN1KMT2ADHPSPRSS1PRSS2 | |
| SCHEMBL4104867 | 1.00 | MEN1 (1.00) | MEN1KMT2ADHPSPRSS1PRSS2 | |
| SCHEMBL5812638 | 1.00 | MEN1 (1.00) | MEN1KMT2ADHPSPRSS1PRSS2 | |
| SCHEMBL5300899 | 1.00 | MEN1 (1.00) | MEN1KMT2ADHPSPRSS1PRSS2 | |
| SCHEMBL1138747 | 1.00 | MEN1 (1.00) | MEN1KMT2ADHPSPRSS1PRSS2 | |
| SCHEMBL261682 | 1.00 | MEN1 (1.00) | MEN1KMT2ADHPSPRSS1PRSS2 | |
| SCHEMBL1069234 | 1.00 | MEN1 (1.00) | MEN1KMT2ADHPSPRSS1PRSS2 | |
| SCHEMBL8752675 | 1.00 | MEN1 (1.00) | MEN1KMT2ADHPSPRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112048083-B | Preparation method of guanidino-containing antibacterial polymer for promoting diabetic ulcer skin repair | 宁波大学 | 2022-12-16 | — | — | CN | claimed |
| CN-108117505-A | A kind of preparation method for synthesizing diphenyl ether imidodicarbonic diamide | 杜庶铭 | 2018-06-05 | — | — | CN | claimed |
| CN-112048083-B | Preparation method of guanidino-containing antibacterial polymer for promoting diabetic ulcer skin repair | 宁波大学 | 2022-12-16 | — | — | CN | disclosed |
| CN-112048083-A | Antimicrobial polymer containing guanidino for promoting diabetic ulcer skin repair and preparation method thereof | 宁波大学 | 2020-12-08 | — | — | CN | disclosed |
| CN-105339340-B | Generated base alkaline agent, the alkali reactive composition containing the generated base alkaline agent and production alkali method | 富士胶片和光纯药株式会社 | 2018-10-12 | — | — | CN | disclosed |
| CN-106414461-B | Borate-based generated base alkaline agent and alkali reactive composition containing the generated base alkaline agent | 富士胶片和光纯药株式会社 | 2018-09-11 | — | — | CN | disclosed |
| CN-108117505-A | A kind of preparation method for synthesizing diphenyl ether imidodicarbonic diamide | 杜庶铭 | 2018-06-05 | — | — | CN | disclosed |
| CN-107848963-A | Alkali-producing agent and/or radical-generating agent having acid resistance, and curable resin composition containing same | 和光纯药工业株式会社 | 2018-03-27 | — | — | CN | disclosed |
| CN-106414461-A | BORATE-BASED BASE GENERATOR, AND BASE-REACTIVE COMPOSITION COMPRISING SUCH BASE GENERATOR | 和光纯药工业株式会社 | 2017-02-15 | — | — | CN | disclosed |
| CN-105339340-A | Base generator, base-reactive composition containing said base generator, and base generation method | WAKO PURE CHEM IND LTD | 2016-02-17 | — | — | CN | disclosed |
| US-8871210-B2 | Chemokine receptor antagonists and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-10-28 | — | — | US | disclosed |
| EP-2055705-A1 | COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF | Ono Pharmaceutical CO., LTD. (JP) | 2009-05-06 | — | — | EP | disclosed |
| EP-2042503-A1 | COMPOUND HAVING ACIDIC GROUP WHICH MAY BE PROTECTED, AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-04-01 | — | — | EP | disclosed |
| EP-1961744-A1 | BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-27 | — | — | EP | disclosed |
| EP-1942108-A1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-07-09 | — | — | EP | disclosed |
| US-20080009495-A1 | Compound Containing Basic Group and Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-01-10 | — | — | US | disclosed |
| EP-1852432-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-07 | — | — | EP | disclosed |
| EP-1790639-A1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-30 | — | — | EP | disclosed |
| EP-1080091-A1 | NOVEL 1,3,8-TRIAZASPIRO[4.5]DECANONES WITH HIGH AFFINITY FOR OPIOID RECEPTOR SUBTYPES | Novo Nordisk A/S (DK) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999059997-A1 | NOVEL 1,3,8-TRIAZASPIRO[4.5]DECANONES WITH HIGH AFFINITY FOR OPIOID RECEPTOR SUBTYPES | NOVO NORDISK A/S (DK) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009495-A1 | Compound Containing Basic Group and Use Thereof | CXCR4, CCR5, CXCR3 | MEN1 2163/4885KMT2A 3544/4885DHPS 1701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.